DUBLIN–(BUSINESS WIRE)–The “Multiple
Myeloma: Epidemiology Forecast to 2027” report has been added
to ResearchAndMarkets.com’s offering.
In 2017, the 8MM had 81,380 diagnosed incident cases of MM. This is
expected to increase to 103,272 diagnosed incident cases by 2027, at an
Annual Growth Rate (AGR) of 2.69%. The increase is driven by the aging
population in the 8MM. In 2017, the 8MM had 353,890 diagnosed prevalent
cases of MM. This is expected to increase to 555,243 diagnosed prevalent
cases by 2027, at an AGR of 5.69%. The US had the highest number of
diagnosed incident and diagnosed prevalent cases of MM. The development
of more effective therapies, particularly for elderly patients, would
improve survival and increase disease prevalence.
The epidemiological forecast for the diagnosed incident cases of MM in
the 8MM is supported by country-specific data for the age- and
sex-specific diagnosed incidence of MM. Additionally, the author
adjusted the forecast to account for coding changes in MM diagnosis
after 2014. The use of a consistent methodology across the 8MM to
forecast the diagnosed incident cases and the diagnosed prevalent cases
of MM allows for a meaningful comparison of the forecast incident cases
and the forecast prevalent cases of MM in these markets.
Scope
The Multiple Myeloma Epidemiology Report provides an overview of the
risk factors and global trends of multiple myeloma in the eight major
markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China
(Urban)). This report also includes a 10-year epidemiological forecast
for the following segmentations
- Diagnosed incident cases of MM
- Diagnosed prevalent cases of MM
- Diagnosed incident cases of MM by symptom status
- Diagnosed incident cases by stem cell transplantation (SCT) eligibility
-
Diagnosed incident cases by high-risk cytogenetics (chromosomal
abnormalities): t(4;14), t(14;16), t(14;20), and del(17/17p) -
Diagnosed incident cases by revised-international staging system
(R-ISS) staging -
The multiple myeloma epidemiology report is written and developed by
Masters- and PhD-level epidemiologists. -
The Epidemiology Report is in-depth, high quality, transparent and
market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to Buy
The Multiple Myeloma Epidemiology report will allow you to –
-
Develop business strategies by understanding the trends shaping and
driving the global multiple myeloma market. -
Quantify patient populations in the global multiple myeloma market to
improve product design, pricing, and launch plans. -
Organize sales and marketing efforts by identifying the age groups and
sex that present the best opportunities for multiple myeloma
therapeutics in each of the markets covered. -
Understand magnitude of multiple myeloma patient population by risk,
SCT eligibility, and R-ISS stages.
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Multiple Myeloma: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 Diagnosed Incidence of MM
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Incident Cases of MM
3.4.4 Diagnosed Incident Cases of MM by Symptom Status
3.4.5 Diagnosed Incident Cases of MM by SCT Eligibility
3.4.6 Diagnosed Incident Cases of MM by Chromosomal Abnormalities
3.4.7 Diagnosed Incident Cases of MM by R-ISS Staging
3.4.8 Diagnosed Prevalent Cases of MM
3.5 Epidemiological Forecast for Multiple Myeloma (2017-2027)
3.5.1 Diagnosed Incident Cases of MM
3.5.2 Age-Specific Diagnosed Incident Cases of MM
3.5.3 Sex-Specific Diagnosed Incident Cases of MM
3.5.4 Diagnosed Incident Cases of MM by Symptom Status
3.5.5 Diagnosed Incident Cases of MM by SCT Eligibility
3.5.6 Diagnosed Incident Cases of MM by Chromosomal Abnormalities
3.5.7 Diagnosed Incident Cases of MM by R-ISS Staging
3.5.8 Diagnosed Prevalent Cases of MM
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/1wzdif
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Leukemia
Drugs